Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021)

Historic Asset Writedowns and Impairment for Karyopharm Therapeutics (KPTI) over the last 2 years, with Q3 2021 value amounting to $200000.0.

  • Karyopharm Therapeutics' Asset Writedowns and Impairment changed N/A to $200000.0 in Q3 2021 from the same period last year, while for Mar 2022 it was $382000.0, marking a year-over-year decrease of 705.6%. This contributed to the annual value of $329000.0 for FY2020, which is N/A changed from last year.
  • Karyopharm Therapeutics' Asset Writedowns and Impairment amounted to $200000.0 in Q3 2021.
  • Karyopharm Therapeutics' 5-year Asset Writedowns and Impairment high stood at $329000.0 for Q4 2020, and its period low was $82000.0 during Q1 2021.